Phillips-Medisize Enhances Integrated Connected Health Platform

Phillips-Medisize, a Molex company, announced the release of its third generation connected health platform, a service offering for its pharma and drug delivery device clients. The platform builds on the success of the company’s first connected health solutions, including the first FDA-approved combination product for medication adherence, and incorporates more than a decade of experience in developing connected health solutions.

Utilizing connectivity in drug delivery devices such as injectors and inhalers, connected health solutions help pharmaceutical companies, healthcare professionals and patients, improve how people take their medication. In addition to medication tracking, these systems support patients through reminders, incentives and peer communities to improve disease management, medication adherence and, ideally, outcomes.

Phillips-Medisize teamed with industry-leading healthcare IT providers to develop a platform that addresses the key challenges faced by the industry. The cloud-based third generation connected health platform is a secure, reliable and scalable medical device data system (MDDS). Using an industry-leading health integration engine combined with a rich analytics tool, it can integrate patient data with electronical medical records and other data from pharmacy and IoT devices, allowing customers to conduct insightful analysis focused on improving medication adherence.

“Phillips-Medisize is a leader in connected health systems for medicine currently on the market, supporting patients daily across the globe. This new, advanced connected health platform builds on our deep knowledge and experience,” said Bill Welch, Chief Technology Officer, Phillips-Medisize. “For us, connected health is a strategy for better serving our customers and their patients, not a buzz word. We are unmatched in the industry with our global innovation, development and manufacturing capabilities to create end-to-end systems.”

As connected health systems begin to demonstrate incremental improvements in adherence and patient outcomes, Phillips-Medisize expects the market to grow. The third generation platform further demonstrates the company’s commitment to meeting industry, provider and patient needs by building technology that is sensible, scalable and cost-effective.